We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy
EP20569
Abstract: Combination therapies are being increasingly employed to treat diseases where single agents do not have the desired clinical benefit. There are a number of publications that cite the benefit of combination therapy over monotherapy in preventing disease progression.Summary: This study aimed to assess if the CFC assay could also be useful at predicting the increased toxicity of drug combinations relative to the toxicity caused by the relevant single agent.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Related Posters
Health vision 2030: An Era of Evolution and Revolution in India
GAURAV JAIN
Clinical and Scientific Evidence for the Safety and Efficacy of XanMax® Lutein/Zeaxanthin
Priya, M.K., Lelah, M.
Lutein Esters are more Bioavailable than Free Lutein
Michael Lelah
Primary Human Hepatocytes 3D in vitro Culture Model for Studying Hepatic Function
Sujoy Lahiri, Julia Tritapoe, Kate Comstock, Michael F. Millett, Mark Kennedy, Theresa V. Nguyen, Deborah K. Tieberg, David T. Kuninger
VITVO: Mimicking In Vivo Complexity By The Innovative 3D Model
Olivia Candini1, Giulia Grisendi1, Elisabetta Manuela Foppiani1, Matteo Brogli1, Beatrice Aramini2, Valentina Masciale3, Carlotta Spano1, Tiziana Petrachi4, Elena Veronesi4, Pierfranco Conte5,6, Giorgio Mari1 & Massimo Dominici1,3